Cafergot
Ocuflox
Nifedipine
Estradiol |
|||
|
Julie message: 1 date: wed, 17 jan 2007 : 47 -0600 from: ellen vander galien subject: perimenopause to: np clinical message-id: 001401c73a93$03865fd0$ 2f01a8c0 at u8j9m0 content-type: text plain; charset iso-8859-1 have two endocrine questions for all of you how useful do you find the measurement of fsh and estradiol during the perimenopause. Thomas, D. M. and D. M. Kuhn 2005 ; . "MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity." Brain Res 1050 1-2 ; : 190-8. Thomas, D. M. and D. M. Kuhn 2005 ; . "Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity." J Pharmacol Exp Ther 313 2 ; : 870-6. Thomas, D. M. and D. M. Kuhn 2005 ; . "Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine." J Neurochem 92 4 ; : 790-7. Thomas, D. M., P. D. Walker, et al. 2004 ; . "Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation." J Pharmacol Exp Ther 311 1 ; : 1-7. Timar, J., S. Gyarmati, et al. 2003 ; . "Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives." Behav Pharmacol 14 3 ; : 199-206. Tolwani, R. J., M. W. Jakowec, et al. 1999 ; . "Experimental models of Parkinson's disease: Insights from many models." Lab Anim Sci 49 4 ; : 363-71. Tomas-Camardiel, M., M. C. Sanchez-Hidalgo, M. J. Sanchez del Pino, A. Navarro, A. Machado and J. Cano 2002 ; . "Comparative study of the neuroprotective effect of dehydroepiandrosterone and 17beta-estradiol against 1-methyl-4-phenylpyridium toxicity on rat striatum." Neuroscience 109 3 ; : 569-84. Truong, J. G., D. G. Wilkins, et al. 2005 ; . "Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: Implications for neurotoxicity." J Pharmacol Exp Ther 314 3 ; : 1087-92. Tsao, L. I., B. Ladenheim, et al. 1998 ; . "Delta opioid peptide [D-Ala2, D-leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: Involvement of opioid receptors and reactive oxygen species." J Pharmacol Exp Ther 287 1 ; : 322-31. Vajragupta, O., P. Boonchoong, et al. 2003 ; . "Manganese-based complexes of radical scavengers as neuroprotective agents." Bioorg Med Chem 11 10 ; : 2329-37. Vajragupta, O., O. Monthakantirat, et al. 2000 ; . "Chroman amide 12P inhibition of lipid peroxidation and protection against learning and memory impairment." Life Sci 67 14 ; : 1725-34. Villemagne, V., J. Yuan, et al. 1998 ; . "Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35, 428 positron emission tomography studies and direct in vitro determinations." J Neurosci 18 1 ; : 419-27. Virmani, A., F. Gaetani, et al. 2005 ; . "Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: Metabolic inhibitors, MPTP, and methamphetamine." Ann N Y Acad Sci 1053: 183-91. Virmani, A., F. Gaetani, et al. 2003 ; . "Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity." Ann N Y Acad Sci 993: 197-207; discussion 287-8. Virmani, A., F. Gaetani, S. Imam, Z. Binienda and S. Ali 2002 ; . "The protective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction." Ann N Y Acad Sci 965: 225-32. Vorhees, C. V. 1997 ; . "Methods for detecting long-term CNS dysfunction after prenatal exposure to neurotoxins." Drug Chem Toxicol 20 4 ; : 387-99. Vorhees, C. V. and C. Pu 1995 ; . "Ontogeny of methamphetamine-induced neurotoxicity in the rat model." NIDA Res Monogr 158: 14971. Vilagi, I., J. Takacs, A. Gulyas-Kovacs, I. Banczerowski-Pelyhe and I. Tarnawa 2002 ; . "Protective effect of the antiepileptic drug candidate talampanel against ampa-induced striatal neurotoxicity in neonatal rats." Brain Res Bull 59 1 ; : 35-40. Virmani, A., F. Gaetani, et al. 2005 ; . "Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: Metabolic inhibitors, MPTP, and methamphetamine." Ann N Y Acad Sci 1053: 183-91. Virmani, A., F. Gaetani, et al. 2003 ; . "Possible mechanism for the neuroprotective effects of L-carnitine on methamphetamine-evoked neurotoxicity." Ann N Y Acad Sci 993: 197-207; discussion 287-8. Vorhees, C. V. 1994 ; . "Developmental neurotoxicity induced by therapeutic and illicit drugs." Environ Health Perspect 102 Suppl 2: 145-53. Wagner, G. C. and S. L. Walsh 1991 ; . "Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage." Int J Dev Neurosci 9 2 ; : 171-4. Wagner, G. C., C. R. Schuster, et al. 1981 ; . "Neurochemical consequences following administration of CNS stimulants to the neonatal rat." Pharmacol Biochem Behav 14 1 ; : 117-9. Wahnschaffe, U. and J. Esslen 1985 ; . "Structural evidence for the neurotoxicity of methylamphetamine in the frontal cortex of gerbils Meriones unguiculatus ; : A light and electron microscopical study." Brain Res 337 2 ; : 299-310. Wakayama, A., K. Kataoka, et al. 1993 ; . "Evaluation of masked neurological disorders in the chronic stage after middle cerebral artery occlusion in rats--methamphetamine-induced rotation and regional glucose metabolism in basal ganglia." Neurol Med Chir Tokyo ; 33 12 ; : 801-8. Aidan Searle, Paul Norman & Kav Vedhara. MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, . UK. Aims This research aimed to elucidate the health beliefs of individuals with a partner with type 2 diabetes. As part of this, we will examine whether health beliefs of the partner vary according to the partner's gender; and the extent to which partners representations influence patients' emotional well-being anxiety and depression ; and dyadic adjustment. Method The Revised Illness Perception Questionnaire IPQ-R ; was utilised to assess the representations of partners' beliefs about type 2 diabetes N 164 ; . The emotional well-being of patients was assessed with the Hospital Anxiety and Depression Scale and dyadic adjustment was assessed with the Dyadic Adjustment Scale DAS ; . Results Analyses will be conducted to 1 ; examine if gender differences exist for partners representations of type 2 diabetes and 2 ; explore whether the relationships between partner health beliefs and patients' emotional well-being and dyadic adjustment are influenced by the gender of the partner. Conclusion The results of these analyses will be discussed in the symposium in the context of dyadic relationships and emotional well-being with chronic disease. Disopyramide Norpace ; , 144 Disseminated Intravascular Coagulation Screen, 144 Disulfiram Antabuse ; , 144 Diuretic Screen Thiazide ; , 144 DNA Analysis, 145 DNA Probe Test Chlamydia Trachomatis. See Genetic Probe: Chlamydia Trachomatis DNA Probe Test Neisseria Gonorrhoeae. See Genetic Probe: Neisseria Gonorrhoeae Doxepin & N-Desmethyldoxepin, 145 Drug Screen, Comprehensive, 146 Drug Screen, Qualitative, Serum, 146 Drug Screen, Qualitative, Urine, 146 DSPC. See Saturated Phosphatidylcholine D-Xylose. See Xylose Absorption Test E E1. See Estrone E2 Estradiol-Beta. See Estraiol Eastern Equine Encephalitis. See Arbovirus Panel EBV Clonality Southern Blot, 148 EBV Panel. See Epstein-Barr Panel Echinococcus Antibody IgG Index ; , 148 Echovirus Antibody, 148 Ehrlichia Chaffeenis Antibody, 148 Eighth Complement Component. See C8 Electrolyte Panel, 149 Emergency Release of Blood, 333 ENA Panel, 149 Endomysial Antibody, 150 Endotoxins, gram negative. See Limulus Amoebocyte Lysate Assay Entamoeba histolytica Antibody, 150 Enterobius Vermicularis Preparation. See Pinworm Preparation Eosinophil Stool, 151 Eosinophil Count Blood, 150 Epidermal Skin ; Antibody, 151 Epstein-Barr Panel, 151 Erythrocyte Folic Acid. See RBC Folate Erythrocyte Sedimentation Rate, 152 Erythropoietin, 152 ESR. See Erythrocyte Sedimentation Rate Estradiol, 153 Estrone E1 ; , 153. Unbonded silica particles are extremely unstable in alkaline mobile phases. The failure mechanism generally accepted as predominant is nucleophilic attack by hydroxide ions on its structural siloxane bonds. XBridgeTM particles exhibit excellent resistance to high pH solutions, even prior to bonding, due to the presence of structural ethylene bridges which do not easily hydrolyze. Up to six siloxane bonds would have to be broken to free one ethylene-bridge unit. This fact, coupled with the excellent mechanical strength of the particle, explains the exceptional lifetime of XBridgeTM columns in high pH mobile phases. One well-documented characteristic of tumor promotion is that it is reversible up to a certain point. Therefore, we determined whether promoter-induced resistance to apoptosis is reversible using U93 7 cells that were cultured in the presence of aflatoxin 0.1 nM ; , 3-estradiol 1.0 nM ; , or prolactin 1.0 U ml ; for 14 days, followed by culture in fresh medium. After 14 days of culture in the promoters, the cells were completely resistant to TNF-induced apoptosis data not shown ; . However, after 21 days of culture without promoter, these cells regained sensitivity, in contrast to the complete resistance exhibited by cells cultured in promoters for the entire 35-day period Fig. 3 ; . During the entire culture period, we observed no obvious promoter-induced alterations in cell morphology as revealed by light microscopy; nor were there any apparent changes in growth rate as reflected by cell counts every 2-3 days. These findings support the hypothesis that tumor promotion involves prolonged exposure to agents that inhibit apoptosis in a reversible manner and famotidine. Table 1 Clinical features of children with asthma positive for IgEanti-endothelial cell antibodies Absence of IgEAECA No. patients Age years ; Sex ratio females males ; Atopic dermatitis n ; Percentage Total IgE IU mL ; Mite-specific IgE score ; Detection of anti-75 kDa antibody n ; Percentage 131 5.7 3.8 Presence of IgEAECA 25 1.8 1.6 P 0.01 NS NS 0.01. Several human UGTs including UGT1A8, UGT1A10, UGT1A1, and UGT1A3 significantly glucuronidated estradiol at the 3-position Table 2 ; . However, the role of UGT1A8 and UGT1A10 in the hepatic glucuronidation of estradiol would be negligible, since previous work has shown a lack of expression in the liver Strassburg et al., 1997 ; . Furthermore, Senafi et al. 1994 ; used microsomes from the livers of Crigler-Najjar patients, who are genetically devoid of UGT1A1, to demonstrate that the majority of estradiol-3-glucuronidation in human liver is catalyzed by UGT1A1. In contrast, estradiol17-glucuronidation was catalyzed by several hepatic forms, UGT1A3, UGT1A4, and UGT2B7, to similar extents. Therefore, with no information regarding relative expression levels of these forms in the available expression systems, it is not possible to determine the individual role these forms play in the production of estradiol-17glucuronide. Naphthol glucuronidation has historically been used as a selective substrate for UGT1A6 in liver microsomes even though its glucuronidation has been shown to be catalyzed by a number of UGT isoforms Burchell et al., 1995, 2001 ; . This view is supported by the data in the current study Table 2 ; . Naphthol glucuronidation mediated by UGT1A6 was found to be over 24-fold greater than by any other UGT form known to be expressed in the liver. In addition to this extensive rate of glucuronidation, recent studies have illustrated that the UGT1A6-mediated glucuronidation of naphthol has a 4-fold greater affinity than that catalyzed by UGT2B7 Soars et al., 2003a, b ; . Propofol glucuronidation was catalyzed by UGT1A9 in the current study at a rate over 90-fold greater than that observed by other hepatic UGT forms. Hence, propofol appears to be a suitable selective probe and fexofenadine. I worry that my daughter will fall into drugs, mancillas said. Generic Name etodolac fenoprofen fenoprofen flurbiprofen flurbiprofen ibuprofen ibuprofen indomethacin indomethacin ketoprofen ketoprofen ketoprofen ER ketorolac injectable ; meclofenamate mefenamic acid meloxicam nabumetone nabumetone naproxen naproxen naproxen sodium naproxen sodium naproxen sodium oxaprozin oxaprozin piroxicam piroxicam rofecoxib salsalate salsalate sulindac sulindac tolmetin tolmetin valdecoxib 5. Estrogens conj. estogens conj. estogens cream ; conj. estogens conj. estogens medroxypr. conj. estogens medroxypr. estradiol estradiol estradiol cream ; estradiol patch ; estradiol patch ; estradiol patch ; estradiol patch ; estradiol patch ; estradiol norethindrone estradiol norethindrone patch and pseudoephedrine. Laboratory tests estrogen administration should be initiated at the lowest dose approved for the indication and then guided by clinical response rather than by serum hormone levels , estradiol, fsh. Guide for use: Captures the maintenance pharmacotherapy drug type provided. Any changes to the Pharmacotherapy Type for Main Service Provided will need to be captured. Used in conjunction with the data element Main Service Provided. This is a multiple response item and finasteride. Cancer can diminish the estrogenic activity. breast cancer cells; tibolone and its metabolites Org 30126 and Org 4094 at 5 108 M ; significantly increase the conversion of E1 to estrogen sulphates see Fig. 5 ; . It remarkable that this stimulatory effect occurs at low doses. At high concentrations 5 106 or 5 105 M ; , we observed either no effect or an inhibitory effect of the sulphotransferase activity. The 4-en isomer of tibolone Org OM38 ; shows no stimulatory effect [28]. on the inhibition of estrone-sulphatase and 17-HSD enzymes involved in the formation of estradiol in breast cancer cells. Recent data show also that some progestins promegestone, nomegestrol acetate, medrogestone ; as well as tibolone in hormone-dependent breast cancer cells can stimulate sulphotransferase activity. This is an important point in the physiopathology of this disease because it is well known that the estrogen sulphates are biologically inactive. For these inhibitory or stimulatory effects on the control of the enzymes involved in the formation and transformation of estrogens in breast cancer, we propose the concept of: Selective Estrogen Enzyme Modulator SEEM ; Fig. 6 ; . The exploration of various progestins, tibolone and its metabolites, in trials with breast cancer patients, showing an inhibitory effect on sulphatases and 17-HSD and a stimulatory effect on sulphotransferases, will provide a new possibility in the treatment of this disease. The paradoxical effect of E2 in blocking sulphatase activity in breast cancer cells could be related to estrogen replacement therapy in which it is observed that this treatment in post-menopausal women has no effect or can reduce breast cancer mortality [29, 30]. References. Effects of phytoestrogens on PSA and VEGF expression in LNCaP prostate cancer cells Thelen P. Georg-August-University, Gttingen, Germany Objective: Both vascular endothelial growth factor VEGF ; as an inducer of tumour angiogenesis and prostate-specific antigen PSA ; as a growth factor regulator play significant roles in the progression of hormone dependent prostate cancer PCa ; . Both are stimulated by steroid hormones and altering their secretion could be a useful approach to control progression. We investigated the protective potential of phytoestrogen extracts from Agnus castus AC ; , Cimicifuga racemosa CR ; , Silybum marianum SM ; and Belamcanda chinensis BC ; on LNCaP prostate cancer cells. Design and Method: We used real time RT-PCR to quantify mRNA expression of VEGF and PSA and ELISA for protein secretion in conditioned media of LNCaP. Phytoestrogens were compared to dihydrotestosterone DHT ; and 17--estradiol E 2 ; . Results: Phytoestrogens, E2 and DHT affected expression of VEGF and PSA in a concentration and time dependent manner. After 24h DHT stimulation mRNA of PSA was up-regulated threefold and mRNA of VEGF tenfold. E2 up-regulated VEGF mRNA threefold, VEGF protein fivefold and PSA secretion was doubled after 48h. AC stimulated VEGF secretion up to 26% while PSA expression remained unaltered. CR had no effect on VEGF expression and reduced PSA secretion by 18%. SM reduced VEGF by 24% and PSA by 37%. BC stimulated VEGF up to 46% but reduced PSA secretion by 76%. Conclusions: Phytoestrogen containing plant extracts modify expression of VEGF and PSA. Both estrogenic and anti-estrogenic actions are exerted. Thus, extracts from AC, CR, SM and BC may be a source of yet unknown compounds which regulate growth of steroid dependent PCa cells. Dual 5 alpha ? reductase inhibitor, dutasteride, inhibits androgen action, cellgrowth viability in prostate cancer cell lines Lazier CB * , Thomas L * , Douglas R * , Schmidt L, Tindall DJ Department of Biochemistry and Molecular Biology * Dalhousie University, Halifax, NS, Canada and Departments of Biochemistry Molecular Biology and Urology, Mayo Clinic, Rochester, MN, USA Introduction and objectives: 5-alpha-reductase 5aR ; catalysis of testosterone T ; to dihydrotestosterone DHT ; amplifies androgen action. Our objective was to investigate actions of dutasteride, a novel dual 5aR inhibitor, on prostate cancer PCa ; cell lines. Design and methods: PSA prostate specific antigen ; levels were measured by RIA. Cell growth and viability were assessed by specific assays including Annexin V staining and BrdU uptake. 56 and flagyl. It may be useful in other situations, such as patients with patent foramen ovale pfo ; , those whose stroke followed a heart attack, or in high-risk patients who cannot take antiplatelet drugs, because levonorgestrel and ethinyl estradiol. Ethinyl estradiol and levonorgestrel brand namesThese data are from the 2004 Monitoring the Future Survey, funded by the National Institute on Drug Abuse, National Institutes of Health, DHHS, and conducted by the University of Michigan's Institute for Social Research. The survey has tracked 12th-graders' illicit drug use and related attitudes since 1975; in 1991, 8th- and 10th-graders were added to the study. The latest data are online at drugabuse.gov. * "Lifetime" refers to use at least once during a respondent's lifetime. "Annual" refers to use at least once during the year preceding an individual's response to the survey. "30-day" refers to use at least once during the 30 days preceding an individual's response to the survey. * NSDUH formerly known as the National Household Survey on Drug Abuse ; is an annual survey conducted by the Substance Abuse and Mental Health Services Administration. Copies of the latest survey are available at samhsa.gov. * These data are from the annual Drug Abuse Warning Network, funded by the Substance Abuse and Mental Health Services Administration, DHHS. The survey provides information about emergency department visits that are induced by or related to the use of an illicit drug or the nonmedical use of a legal drug. The latest data 2002 ; are at samhsa.gov, for example, estradiol low. 700 Alexander Park Princeton, NJ 08540 Phone: 609-514-5366 Fax: 609-514-5377 Web: photosound Founded: 1972 Parent company: HealthSTAR Communications, Inc., Woodbridge, N.J. Officers: Tony Mortlock, chief executive officer; Valerie Mortlock, chief operating officer; Jeremy Williams, president; Siew Chee Kong, financial director; Mathew Cutts, director, operations; Neil Madden, assoc. director, client services, Europe; Jane Ringe, v.p., operations U.S. office Patrick De Feo, v.p., finance, human resources and administration; Dawn Bock, assoc. director, client services U.S and galantamine. Estradiol tablets side effects120 100 Steroid concentration logM ; Fig.1. Dose-dependent effects of 11-ketotestosterone 11KT ; , testosterone T ; , cortisol C ; and estrradiol E2 ; on contractile force of ventricle strips from male A ; and female B ; rainbow trout. At the concentrations tested, contractile force in E2-treated ventricle strips from males did not differ from that in control strips. Likewise, 11KT- or T-treated strips from females did not differ from control strips. Values are means + S.E.M. N 710 strips ; for maximal response at each concentration and glibenclamide. HCG and GnRH administration cows received a single IM injection of 8g of GnRH Receptal, Intervet ; on day 7 post breeding. Group III n 10 ; cows were kept as control with placebo injection of saline on day 7 post breeding. 3. Blood collection: All cows were bled via the coccygeal vien on day 0, 7 and 14 after insemination for plasma progesterone estimation. All blood samples were centrifuged at 3000 rpm for 10 minutes with in one hour of collection and plasma separated and frozen at 20o C in eppendrof vials until further assay of hormone. 4. Breeding Artificial insemination was done with good quality of frozen semen loaded with French mini straw, after detection of estrus. 5. Conception rates Pregnancy was confirmed by rectal palpation in all the treated and control groups of cows 45 days post insemination. 6. Hormonal assay The plasma progesterone level was estimated using solid-phase Radio Immuno Assay technique with the help of progesterone kits CoatA count, Diagnostic products Corparation A ; . The Radioactivity was measured in I125 RIASTARPACKARD 5405, USA ; gamma counter. RESULTS AND DISCUSSION The rationale for the administration of hCG and GnRH on day 7 was to enhance the existing corpus luteum function or by forming accessory CL thus improving the pregnancy rate by increased progesterone production early in the cycle. The increase in CL number and thus total CL tissue area was most likely responsible for the increased serum concentrations of progesterone observed. In the 96 present study, The mean progesterone levels at 0, 7 and 14th day post breeding were 0.57 + 0.02, 4.51 + 0.39 and 9.91 + 0.82; 0.50 + 0.05, 5.01 + 0.67 and 7.53 + 0.53 and 0.43 + 0.04, 3.16 + 0.11 and 4.73 + 0.64 for group I, group II and group III cows respectively. hCG treated group had significantly higher progesterone concentrations on day 14 than that of GnRH and control group. In our study, the cows treated with GnRH on day 7 recorded 50 per cent conception when compared to the hCG and control group of cows which showed a conception rate of 30 per cent each. Thatcher et al 1989 ; and Mann and Picton 1995 ; reported that GnRH acts on the follicles present during the time of treatment, leading to either atresia, luteinisation or ovulation followed by luteinisation. Therefore, a reduction in oestradiol secretion expected at this time might inhibit the luteolytic mechanism by way of delay or reduced release of PGF2 from the endometrium and allowing some pregnancies to continue. Further, Pritchard et al. 1994 ; observed that lower serum concentration of extradiol during day 14 -17 post insemination resulted in higher pregnancy rates in lactating cows. The increase in pregnancy rate after GnRH administration observed in this study might be due to luteinisation of follicles, reduced oestradiol secretion, inhibition of luteolysis Mann and Picton, 1995 ; . The failure of hCG to improve the pregnancy rate was might be due improved concentration of progesterone, release of PGF2 from uterine endometrium causing luteolysis as reported by Garret et al. 1987 and 1988 ; and Nogueira et al. 2004 ; . CONCLUSION GnRH administration on day 7 post insemination facilitated a protective endocrine environment which improved the conception rate. The side effects that usually are caused by acne medicines must be taken into account when you decide going under a treatment and glucovance and estradiol, because b estradiol. Systolic stress relation represents a more appropriate index of performance because it considers different myocardial fiber displacements in the hypertrophic left ventricular wall; this index was lower even in asymptomatic hypertensive patients at rest.32 The results of our study clearly indicate that HRT may contribute to the reduction of LVM. To explain this finding, we can hypothesize several mechanisms. It is known that 17 -estradiol has a powerful calcium antagonist effect on both vascular smooth muscle cells and cardiac fibers.33, 34 Substantial evidence suggests that 17 estradi9l has a significant impact on the renin-angiotensin system; Schunkert et al35 demonstrated that both oral and transdermal HRT is related to a substantial suppression of serum renin levels; on the other hand, an increase in angiotensinogen has been described only in women taking oral estrogen. Proudler et al36 highlighted a 20% reduction in the plasma concentration of ACE after 6 months of treatment with transdermal 17 -estradiol; furthermore, the natural hormone inhibits in vitro the vasoconstriction effect of angiotensin II and therefore is involved in the peripheral sympathetic tone modulation.37 This finding has been demonstrated in humans by Mercuro et al; 38 in this study, the acute administration of transdermal 17 estradiol was associated with a significant reduction of norepinephrine plasma levels in a population of postmenopausal women. In conclusion, transdermal 17 -estradiol, associated with antihypertensive therapy, may contribute to the reduction of LVM in hypertensive postmenopausal women; the mechanisms by which this event occurs is little known and may be multifactorial. Estradiol oral tabletsDiscussion The main differential diagnoses we considered in Ms. Z. were general anxiety disorder, panic disorder, anxiety secondary to hyperthyroidism, and anxiety secondary to pheochromocytoma. Because she did not meet the DSM-IV criteria for either panic disorder or general anxiety disorder and was found to have normal serum TSH and urinary catecholamine levels, we decided on akathisia secondary to Mp therapy as our working diagnosis. The fact that Ms. Z. continued to have symptoms for up to 48 hours after cessation of her last Mp dose is consistent with the kinetics of Mp. Five half-lives for complete elimination would take at least 30 hours. The most crucial piece of evidence confirming our diagnosis was the fact that she had no further episodes of akathisia once the Mp was eliminated from her body. If this had been a form of panic disorder or general anxiety disorder, we would have expected her symptoms to continue after discharge and especially after her phenobarbital course was finished. We believe that this is one of the first reports of Mp-induced akathisia during pregnancy. There are several case reports and reviews of anxiety disorders in pregnant and postpartum women, 16, 17 but we have no reports of Mp-induced akathisia during pregnancy in the MEDLINE search 1969 to 1999 ; we performed. The extensive biological changes associated with pregnancy have been reviewed.16 These changes occur in the central nervous system and in the periphery and may impact both the pharmacokinetics of Mp and how a woman reacts to its side effects. We will attempt to summarize some of the changes in pregnancy that may have a role in drug-induced akathisia. Pregnancy is also a period of physiologic upheaval with marked hormonal changes. Foremost among these hormonal effects are the gonadal steroids, which undergo marked changes during pregnancy. Circulating estrogen levels may vary by 100 times during pregnancy from 0.3 ng ml of estradiol at conception to 30 ng near term ; . Most of this increase occurs in the first two trimesters of gestation with estradiol levels averaging 2030 ng ml at Week 21 when Ms. Z. began complaining of restlessPsychosomatics 42: 2, March-April 2001. 1967x ; . National health planning in developing countries . report series, 350 . 1967b ; . Research in psychopharmacology. Estradiol e2Try feeding the baby in a car seat or relaxer chair rather than in your arms. This sometimes works, because the baby feels less constricted and perhaps doesn't pick up on your anxiety. Tube feeding If there is concern that your baby is not taking in adequate amounts with breast or bottlefeeding alone, feeding can be started through a tube. A nasogastric tube NGT ; is placed in the baby' nose and passes to the stomach. s Formula or breast milk is delivered through the tube so the child doesn't have to suck or swallow. An NGT makes the feeding easier and faster: your baby will almost certainly gain more weight. Most babies put up with it surprisingly well, although putting new tubes in is likely to be resisted by any baby not too weak to fight. You may want to learn to repass the tube yourself, or the hospital can arrange for this to be carried out by a community nurse once you are home. Gastrostomy NG tubes hold the stomach muscle open, allowing the contents to spill out, and in some cases stimulate the gag reflex , which can cause vomiting. If your child is likely to need an NGT for a long time, then you may want to consider a gastrostomy. A GT is put in surgically under anaesthetic and a hole is made in the stomach wall. The advantages of having a GT is that your son or daughter will look normal no tubes going through the nose ; . You can also put medicines and food directly into the stomach, but your child is also free to eat and experiment with different foods and tastes. Children have successfully started feeding by mouth later on in life after a gastrostomy. Solid feeding Weaning solids are usually introduced when the baby is about six months old. You may be advised to start earlier at 4-5 months if it will help with weight gain. Many mothers have found that the introduction of solids is a huge help to their baby's progress, mainly because it requires less effort for the baby to eat, and takes much less time. Also, babies tend to fall asleep better after solids. But you will need to maximise the number of calories: try thick yoghurts without bits ; and fromage frais, which have more calories than ordinary yoghurts and baby yoghurts. Other sweet puddings, custards, and porridge all have a high calorie content. What is important to remember is that you don't have to go by the normal `rules' for what is and isn't good for a child. The first priority is that they eat something so don't worry if your baby only seems to want sweet foods. They will eventually eat all kinds of. Estradiol pillsAn opioid antagonist drug called naltrexone naltrexone in the large 50mg size, originally manufactured by dupont under the brand name revia, is now sold by mallinckrodt as depade and by barr laboratories under the generic name naltrexone ; that blocks some endorphin receptors, for example, estradiol symptoms.
|